logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Lyfe, Qiming Lead $70M Series B Round For Chinese Biotech Firm Medilink

Mar 14, 2022•almost 4 years ago

Amount Raised

$70 Million

Round Type

series b

Description

Chinese biotech firm MediLink Therapeutics has secured $70 million in a Series B round of financing to invest in the clinical trials of its pipeline of biological drugs and the early R&D of new products.

Company Information

Company

Medi Link

About

The startup targets to serve unmet medical needs in China by promoting ADC manufacturing — a process that requires heavy capital investment and extensive specialised training for operators — through cross-border collaborations and multi-centre clinical trials. Founded in 2020, MediLink primarily develops antibody-drug conjugates (ADCs) — a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech